A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.
Lymphoma, Mantle-Cell
DRUG: Zanubrutinib|DRUG: Rituximab|DRUG: Bendamustin
2-year Progression-Free Survival, Progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of disease progression or relapse, according to 2014 Lugano criteria, or death from any cause, whichever occurred first., 2 years
ORR, Objective Remission Rate (ORR) is defined as the proportion of patients with complete remission (CR) and partial remission (PR), End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]|CRR, Complete Remission Rate (CRR) is defined as the proportion of patients with CR, End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=28 days]|OS, Overall survival (OS) refers to the time from receiving the first dose to death from any cause, Baseline up to data cut-off (up to approximately 2 years)|Adverse Events, Any harmful reaction that occurs during the treatment of a disease according to the normal usage and dosage of a drug, which is unrelated to the purpose of treatment., Baseline up to data cut-off (up to approximately 2 years)
The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.